Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

Aliment Pharmacol Ther. 2015 Jan;41(1):149. doi: 10.1111/apt.13011.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / blood
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / blood
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Colitis, Ulcerative / drug therapy*
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / blood
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Infliximab
  • Tumor Necrosis Factor Inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • Tumor Necrosis Factor Inhibitors
  • Infliximab
  • Adalimumab